Abbott Laboratories vs. IDEAYA Biosciences, Inc. Common Stock
Abbott Laboratories (ABT) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| ABT | IDYA | |
|---|---|---|
| Market Cap | $194.98 billion | $3.66 billion |
| Revenue (TTM) | $46.59 billion | $234.13 million |
| Net Income (TTM) | $5.42 billion | $-175,020,000 |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | IDYA | |
|---|---|---|
| P/E Ratio | 37.03 | — |
| Price / Book | 3.77 | 3.05 |
| Price / Sales | 4.19 | 15.63 |
ABT and IDYA split the valuation factors evenly.
Profitability
| ABT | IDYA | |
|---|---|---|
| Net Margin | 11.65% | -74.75% |
| Return on Equity | 10.48% | -14.60% |
ABT leads on 2 of 2 profitability factors.
Dividend
| ABT | IDYA | |
|---|---|---|
| Dividend Yield | 2.20% | — |
| Payout Ratio | 81.55 | — |
ABT and IDYA split the dividend factors evenly.
Risk & Sentiment
| ABT | IDYA | |
|---|---|---|
| Short Interest | 0.57% | 0.14% |
IDYA leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, IDYA overview, IDYA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.